INHIBRX BIOSCIENCES, INC. (INBX) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$31.63M; Operating income (m); Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA -$30.39M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$30.36M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$33.23M; Operating income (m); Depreciation and amortization (m).
Complete source-backed ebitda history.
- Available history
- 2023-06-30 to 2026-06-30
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$31.63M | (m) | (m) | (m) | (m) | $0.00* | -$29.92M* | (m) | $23.90M | (m) | $3.00K |
|---|
| 2026-03-31 | Reported | -$30.39M | (m) | (m) | (m) | (m) | $0.00 | -$38.03M | (m) | $25.22M | (m) | $0.00 |
|---|
| 2025-12-31 | Reported | -$30.36M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$33.23M | (m) | (m) | (m) | (m) | $10.00K* | -$33.82M* | (m) | $28.54M | (m) | $0.00 |
|---|
| 2025-06-30 | Reported | -$26.73M | (m) | (m) | (m) | -2055.92% | $0.00* | -$29.95M* | (m) | $22.27M | (m) | $2.00K |
|---|
| 2025-03-31 | Reported | -$42.23M | (m) | (m) | (m) | (m) | $21.00K | -$35.90M | (m) | $36.88M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$49.24M | (m) | (m) | (m) | -49239.00% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$46.04M | (m) | (m) | (m) | (m) | $247.00K* | -$30.28M* | (m) | $38.89M | (m) | $0.00 |
|---|
| 2024-06-30 | Reported | -$160.42M | (m) | (m) | (m) | -160423.00% | $1.22M* | -$57.36M* | (m) | $67.63M | (m) | $2.00K |
|---|
| 2024-03-31 | Reported | -$73.47M | (m) | (m) | (m) | (m) | $1.12M | -$63.05M | (m) | $63.85M | (m) | $0.00 |
|---|
| 2023-12-31 | Reported | -$87.99M | (m) | (m) | (m) | -5385.01% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$45.52M | (m) | (m) | (m) | -38254.62% | $811.00K* | -$54.24M* | (m) | $38.06M | (m) | $2.00K |
|---|
| 2023-06-30 | Reported | -$41.04M | (m) | (m) | (m) | -136813.33% | (m) | (m) | (m) | $34.11M | (m) | $5.00K |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$132.54M | (m) | (m) | (m) | -10195.54% | $31.00K | -$129.79M | (m) | $113.03M | (m) | $2.00K |
|---|
| 2024-12-31 | Reported | -$329.16M | (m) | (m) | (m) | -164581.50% | $2.60M | -$194.41M | (m) | $203.74M | (m) | $2.00K |
|---|
| 2023-12-31 | Reported | -$218.03M | (m) | (m) | (m) | -12112.78% | $4.59M | -$193.31M | (m) | $191.64M | (m) | $3.00K |
|---|